Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Sherman Spotlights Advances With RET Inhibitors in Medullary Thyroid Cancer

July 1st 2021

Dr. Sherman discusses the incidence of RET fusions in medullary thyroid cancer and the current clinical landscape of RET inhibitors in the field.

Leukocyte Interleukin Plus SOC, Without Chemo, Provides 5-Year OS Benefit of 14.1% in Head and Neck Cancer

June 29th 2021

The immunotherapy Leukocyte interleukin followed by surgery and radiotherapy, without chemotherapy, significantly improved overall survival compared with standard of care alone in the treatment of patients with advanced primary squamous cell carcinoma of the head and neck.

Dr. Burtness on the Efficacy of Checkpoint Inhibitors in Head & Neck Cancer

June 29th 2021

Barbara Burtness, MD, discusses the efficacy of immune checkpoint inhibitors in the treatment of patients with head and neck cancer.

Selpercatinib Elicits Encouraging Antitumor Activity in Pediatric RET-Altered Solid Tumors

June 6th 2021

Selpercatinib demonstrated evidence of preliminary efficacy and safety in pediatric patients with advanced RET-altered solid tumors.

Frontline Toripalimab Plus Gemcitabine/Cisplatin Significantly Improves PFS in Recurrent or Metastatic Nasopharyngeal Carcinoma

June 3rd 2021

The addition of the immunotherapy agent toripalimab to gemcitabine plus cisplatin demonstrated superior progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal carcinoma, according to data from the phase 3 JUPITER-02 trial.

Innovation Fuels Breakthroughs for Rare Cancers

June 2nd 2021

Innovative strategies are vital for patients diagnosed with rare cancers, who are frequently at a disadvantage compared with those who have more common malignancies, experts say.

Dr. Owonikoko on the Efficacy of Selpercatinib in Pre-Treated and Untreated RET+ Thyroid Cancer

May 26th 2021

Taofeek Owonikoko MD, PhD, MSCR, discusses the efficacy of selpercatinib in pre-treated and treatment-naive patients with RET fusion–positive medullary thyroid cancer.

Dr. Sosa on Risk Factors for Thyroid Cancer

May 25th 2021

Julie Ann Sosa, MD, MA, FACS, FSSO, discusses risk factors for thyroid cancer.

FDA Approval Sought for Penpulimab in Third-Line Metastatic Nasopharyngeal Carcinoma

May 24th 2021

A biologics license application has been submitted to the FDA for the PD-1 monoclonal antibody penpulimab for the third-line treatment of patients with metastatic nasopharyngeal carcinoma.

Research Efforts Examining Novel Radiation Approaches Flourish at Fox Chase Cancer Center

May 21st 2021

Eric M. Horwitz, MD, FABS, FASTRO, and Stephanie E. Weiss, MD, FASTRO, highlight ongoing research efforts with radiation therapy that are generating excitement at their institution.

Frontline Tislelizumab Plus Chemo Improves PFS in Recurrent or Metastatic Nasopharyngeal Cancer

May 21st 2021

The combination of the anti–PD-1 tislelizumab and chemotherapy was found to significantly improve progression-free survival compared with chemotherapy alone in the frontline treatment of patients with recurrent or metastatic nasopharyngeal cancer, meeting the primary end point of the phase 3 RATIONALE 309 trial.

cfMeDIP-seq Provides Opportunity for Early Cancer Detection, Classification, and Monitoring

May 18th 2021

Cell-free methylated DNA immunoprecipitation-sequencing uses plasma cell-free methylomes to detect and classify several types of cancer early on, and provides the opportunity to monitor tumors for response to treatment in noninvasive way.

Dr. Marron on the Population Included in a Phase 1 Study of PGV-001 Neoantigen Cancer Vaccine

May 13th 2021

Thomas Urban Marron, MD, PhD, describes the patient population included in a phase 1 study examining the use of PGV-001, a neoantigen cancer vaccine, across different malignancies.

Dr. Cohen on Future Research Directions in Head and Neck Cancer

April 29th 2021

Ezra Cohen, MD, FRCPSC, FASCO, discusses future research directions for the treatment of patients with head and neck cancer.

Managing the Complexities of Nasopharyngeal Cancer

April 21st 2021

Although the malignancy has an encouraging survival rate, it is necessary to be aware of the complexity of nasopharyngeal cancer.

Saba Spotlights the Nuances of Treating Nasopharyngeal Cancer

April 19th 2021

Dr. Saba shares the ins and outs of nasopharyngeal carcinoma, ongoing clinical trials, and the complexities of managing the rare disease.

Dr. Saba on Unique Characteristics of Nasopharyngeal Carcinoma

April 15th 2021

Nabil F. Saba, MD, FACP, discusses some of the unique characteristics of nasopharyngeal carcinoma.

Single Port Robotic ENT Surgery Takes Throat and Mouth Tumor Treatment to ‘A New Level’

April 14th 2021

Innovative robotic technology helps to improve surgical outcomes and safety for patients while advancing the field of ENT surgery.

Dr. Marron on an Adjuvant Personalized Neoantigen Peptide Vaccine for Several Malignancies

April 10th 2021

Thomas Urban Marron, MD, PhD, discusses primary objectives of a study examining the use of an adjuvant personalized neoantigen peptide vaccine in several malignancies.

FDA Grants Fast Track Status to Eftilagimod Alpha for Frontline Recurrent/Metastatic Head and Neck Cancer

April 8th 2021

The FDA has granted a fast track designation to the soluble LAG-3 protein eftilagimod alpha for use in the frontline treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma.